ZimVie reports strong Q2 revenue of $117 million and maintains full-year revenue guidance

From Investing.com: 2024-08-04 20:15:06

ZimVie (ZIMV) reported Q2 2024 revenue of $117 million, with plans to maintain full-year revenue guidance of $450-$460 million. FDA clearance for GenTek Restorative Components in the US and partnerships with Medit for scanner distribution show strong focus on innovation and market expansion. The company aims for 15% plus EBITDA margins one year post-spine sale.

ZimVie continues to strengthen its product offerings with new dental implants TSX and T3 PRO, showing strong commercial traction. The company’s biomaterials portfolio outpaces market growth. Positive performance in Asia Pacific markets, particularly in Japan, India, and Australia, further demonstrates ZimVie’s strategic direction for long-term growth and market stability.



Read more at Investing.com: ZimVie maintains guidance amid Q2 revenue of $117 million By Investing.com